Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial.
SIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cells.
Idiopathic inflammatory demyelinating diseases of the brainstem.
Blocking A2B Adenosine Receptor Alleviates Pathogenesis of Experimental Autoimmune Encephalomyelitis via Inhibition of IL-6 Production and Th17 Differentiation.
Liver X Receptors differentially modulate central myelin gene mRNA levels in a region-, age- and isoform-specific manner.
Glutathione in multiple sclerosis: More than just an antioxidant?
Human glial chimeric mice reveal astrocytic dependence of JC virus infection.
Bioenergetics of the spinal cord in experimental autoimmune encephalitis of rats.
Multiple sclerosis: A distinct disease course for paediatric multiple sclerosis.
Cognitive deficit is related to immune-cell beta-NGF in multiple sclerosis patients.
Acute combined central and peripheral demyelination showing anti-aquaporin 4 antibody positivity.
Early versus delayed treatment with laquinimod demonstrated significant reduction in risk of disability progression – Results of three-year ALLEGRO study in relapsing-remitting multiple sclerosis
Defining Encephalopathy in Acute Disseminated Encephalomyelitis.
The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: Diverse roles in modulating immune cell functions.
Therapeutic plasma exchange in neuromyelitis optica: A case series.
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).
Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells.
Alemtuzumab (LEMTRADA) and multiple sclerosis. Biased evaluation, evidence of serious risks.
Choosing the best treatment for multiple sclerosis: comparative effectiveness, safety, and other factors involved in disease-modifying therapy choice.
Antiinflammatory activity of glucomoringin isothiocyanate in a mouse model of experimental autoimmune encephalomyelitis.
Clinical trials to clinical use: using vision as a model for multiple sclerosis and beyond.
mTOR kinase, a key player in the regulation of glial functions: Relevance for the therapy of multiple sclerosis.
Prenatal vitamin d deficiency induces an early and more severe experimental autoimmune encephalomyelitis in the second generation.
Structural and Metabolic Features of Two Different Variants of Multiple Sclerosis: A PET/MRI Study.
B-cell targeted therapeutics in clinical development.

Pages